Back to Market Feed

Product Information

SKYRIZI 150 MG/ML SYRINGE is a brand product labeled by AbbVie Inc., priced at $22887.4386 per ML under NDC 00074105001. Its NADAC has been published 214 times since Jul 20, 2022.

SKYRIZI 150 MG/ML SYRINGE

risankizumab-rzaa
$22887.4386per ML

Strength

150 mg/mL

Manufacturer

AbbVie Inc.

NDC

00074105001

Classification

Brand

Dosage Form

INJECTION

Route

SUBCUTANEOUS

Effective Date

8/19/2026

Active Ingredients

RISANKIZUMAB

Approval Type

Biologic (BLA)

FDA Application

BLA761105

On Market Since

4/26/2021

Pharmacological Classes

Interleukin-23 Antagonist
Interleukin-23 Antagonists

Price Statistics

The NADAC for SKYRIZI 150 MG/ML SYRINGE has been published 214 times since Jul 20, 2022, and over the history we have for it it has risen 28.3%. The table below summarizes its recorded NADAC range and movement.

Current price$22887.4386 per ML
All-time high$22942.3716 (Jul 15, 2026)
All-time low$17835.5520 (Jul 20, 2022)
52-week high$22942.3716
52-week low$21504.5640
Median price$20514.4519
Average price$20487.1182
Largest weekly change+8.0% (Jan 11, 2023)
Weeks tracked214
Tracking sinceJul 20, 2022

Price History

1W

+0.6%

1M

+0.6%

3M

-0.2%

6M

-0.2%

1Y

+6.4%

3Y

+18.8%

5Y

N/A

All

+28.3%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 1%

1 alternative • Same active ingredient

SKYRIZI 150 MG/ML PEN
Brand
00074210001•AbbVie Inc.
$22761.4629
Save 1%

Related Drugs

Same classification

TREMFYA 200 MG/2 ML PEN
Brand
57894065102•Janssen Biotech, Inc.
$7318.9883
per ML
TREMFYA 100 MG/ML SYRINGE
Brand
57894064001•Janssen Biotech, Inc.
$14728.9053
per ML
TREMFYA 100 MG/ML ONE-PRESS
Brand
57894064011•Janssen Biotech, Inc.
$14745.8421
per ML
STELARA 90 MG/ML SYRINGE
Brand
57894006103•Janssen Biotech, Inc.
$29792.7867
per ML
STELARA 45 MG/0.5 ML SYRINGE
Brand
57894006003•Janssen Biotech, Inc.
$29874.4480
per ML

Frequently asked questions

What is the NADAC price of SKYRIZI 150 MG/ML SYRINGE?

The current National Average Drug Acquisition Cost (NADAC) for SKYRIZI 150 MG/ML SYRINGE, manufactured by AbbVie Inc., is $22887.4386 per ML (NDC 00074105001), effective Aug 19, 2026.

How has the price of SKYRIZI 150 MG/ML SYRINGE changed over time?

Over the history we have for it, the NADAC for SKYRIZI 150 MG/ML SYRINGE has risen 28.3%. It has been tracked across 214 weekly CMS publications since Jul 20, 2022.

What are the highest and lowest recorded NADAC prices for SKYRIZI 150 MG/ML SYRINGE?

Since Jul 20, 2022, the NADAC for SKYRIZI 150 MG/ML SYRINGE has ranged from a low of $17835.5520 (Jul 20, 2022) to a high of $22942.3716 (Jul 15, 2026), with a median of $20514.4519 per ML.

Are there cheaper alternatives to SKYRIZI 150 MG/ML SYRINGE?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, SKYRIZI 150 MG/ML PEN, is $22761.4629 per ML — about 1% below SKYRIZI 150 MG/ML SYRINGE.

Who manufactures SKYRIZI 150 MG/ML SYRINGE?

SKYRIZI 150 MG/ML SYRINGE (NDC 00074105001) is labeled by AbbVie Inc., and CMS classifies it as a brand product.